- NewLimit, a longevity startup co-founded by Coinbase CEO Brian Armstrong, has raised $40 million in Series A funding.
- The company is developing new technologies to extend human lifespan. Its initial focus is on epigenetics, which is the study of how genes are turned on and off.
- Byers believes that epigenetics could be used to reprogram cells so that they act younger, which could lead to a longer and healthier life.
- The company’s funding round was led by Kleiner Perkins, with participation from Dimension, Founders Fund, and other investors.
- The company plans to use the funds to hire more scientists and to develop its technologies.
- Armstrong is a strong believer in the potential of longevity research. He has said that he believes that extending human lifespan is one of the most important challenges facing humanity.
- NewLimit is one of several companies that are working to develop new technologies to extend human lifespan.
- The field of longevity research is still in its early stages, but it has the potential to revolutionize the way we think about aging and death.
- If NewLimit and other companies are successful, they could help us to live longer, healthier lives.
Here are some additional details about the company:
- NewLimit was founded in 2021 by Blake Byers, Brian Armstrong, Greg Johnson, and Jacob Kimmel.
- Byers is a former Google Ventures partner with a Stanford Ph.D. in bioengineering. Armstrong is the CEO of Coinbase, the largest cryptocurrency exchange in the United States. Johnson formerly led the development of novel machine learning methods at the Allen Institute for Cell Science. Kimmel led a research laboratory focused on epigenetic reprogramming as a Principal Investigator and Computational Fellow at research and development company Calico.
- NewLimit is headquartered in San Francisco, California.
- The company’s mission is to “cure aging.”
- NewLimit’s approach to curing aging is through epigenetic reprogramming. Epigenetic reprogramming is the process of changing the expression of genes without changing the DNA sequence. This can be done by changing the way that genes are turned on and off.
- NewLimit believes that epigenetic reprogramming can be used to reprogram cells so that they act younger. This could lead to a longer and healthier life.
- NewLimit is still in its early stages of development. The company has not yet published any clinical trials. However, the company has raised $40 million in funding from a group of prominent investors. This suggests that the company has the potential to make a significant impact on the field of longevity research.